Search
aTyr Pharma Ord Shs
LIFEAdd to Watchlist
20.420USD
+0.150+0.74%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.29BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of aTyr Pharma Ord Shs is 8.89, ranking 39 out of 385 in the Biotechnology & Medical Research industry.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
28.000
Target Price
+37.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
aTyr Pharma Ord Shs
LIFE
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is aTyr Pharma Ord Shs's expected revenue for the next quarter?
aTyr Pharma Ord Shs's expected revenue is 120.22M.
How have aTyr Pharma Ord ShsLIFE's recent earnings per share performed?
The market expectation was USD -3.57, while aTyr Pharma Ord ShsLIFE's earnings per share (EPS) for the previous quarter was USD 0.39. EPS for the next quarter is expected at USD 0.24.
What is the analyst rating for aTyr Pharma Ord Shs?
Based on the ratings of aTyr Pharma Ord Shs's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.